Evaluating Early Macrolide Therapy in Pediatric Campylobacter Enterocolitis: A Comparative Study

<b>Background/Objectives:</b> Azithromycin is widely recommended as the first-line treatment for pediatric <i>Campylobacter</i> enterocolitis, although supporting evidence is limited and there is a lack of studies evaluating the efficacy of other macrolide antibiotics. This study aims to assess the effectiveness of starting macrolide therapy within three days of symptom onset in pediatric patients with <i>Campylobacter</i> enterocolitis. <b>Methods:</b> Pediatric patients under 19 years of age with a new diagnosis of <i>Campylobacter</i> enterocolitis were enrolled and randomly assigned to receive macrolide antibiotic treatment with either azithromycin or clarithromycin in a 1:1 ratio. Additionally, a retrospective historical cohort of pediatric patients diagnosed with <i>Campylobacter</i> enterocolitis prior to the study period, who did not receive macrolide antibiotics, was retrospectively reviewed for comparison. This dual approach allowed for the evaluation of macrolide therapy's effectiveness against untreated cases. <b>Results:</b> The study included 27 patients in the macrolide group and 37 patients in the non-macrolide group. Baseline demographic and clinical characteristics were comparable between groups. Early macrolide therapy was associated with reduced hospital stay (3.8 ± 0.7 vs. 4.5 ± 0.9 days), shorter duration of diarrhea (1.8 ± 1.2 vs. 3.4 ± 0.7 days, <i>p</i> < 0.001), and shorter duration of fever (1.1 ± 0.6 vs. 2.8 ± 1.0 days, <i>p</i> < 0.001). No significant difference was observed in the duration of vomiting (<i>p</i> = 0.061). <b>Conclusions:</b> Early initiation of macrolide antibiotics in children with <i>Campylobacter</i> enterocolitis significantly accelerated complete clinical resolution and shortened hospitalization, particularly by hastening the resolution of diarrhea, fever, and abdominal pain. These findings support the use of early macrolide therapy for pediatric <i>Campylobacter</i> enterocolitis.

Authors

Institutions

Publication Details

Journal
Antibiotics
Published
2026-02-05
DOI
https://doi.org/10.3390/antibiotics15020171
Primary Topic
Salmonella and Campylobacter epidemiology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Evaluating Early Macrolide Therapy in Pediatric Campylobacter Enterocolitis: A Comparative Study

In Hyuk Yoo, Ye Ji Kim, Yoon Kyung Cho, Hyun Mi Kang et al.
Antibiotics
Salmonella and Campylobacter epidemiology
article

Evaluating Early Macrolide Therapy in Pediatric Campylobacter Enterocolitis: A Comparative Study

In Hyuk Yoo, Ye Ji Kim, Yoon Kyung Cho, Hyun Mi Kang, Dae Chul Jeong, H. Choi
article en

Abstract

<b>Background/Objectives:</b> Azithromycin is widely recommended as the first-line treatment for pediatric <i>Campylobacter</i> enterocolitis, although supporting evidence is limited and there is a lack of studies evaluating the efficacy of other macrolide antibiotics. This study aims to assess the effectiveness of starting macrolide therapy within three days of symptom onset in pediatric patients with <i>Campylobacter</i> enterocolitis. <b>Methods:</b> Pediatric patients under 19 years of age with a new diagnosis of <i>Campylobacter</i> enterocolitis were enrolled and randomly assigned to receive macrolide antibiotic treatment with either azithromycin or clarithromycin in a 1:1 ratio. Additionally, a retrospective historical cohort of pediatric patients diagnosed with <i>Campylobacter</i> enterocolitis prior to the study period, who did not receive macrolide antibiotics, was retrospectively reviewed for comparison. This dual approach allowed for the evaluation of macrolide therapy's effectiveness against untreated cases. <b>Results:</b> The study included 27 patients in the macrolide group and 37 patients in the non-macrolide group. Baseline demographic and clinical characteristics were comparable between groups. Early macrolide therapy was associated with reduced hospital stay (3.8 ± 0.7 vs. 4.5 ± 0.9 days), shorter duration of diarrhea (1.8 ± 1.2 vs. 3.4 ± 0.7 days, <i>p</i> < 0.001), and shorter duration of fever (1.1 ± 0.6 vs. 2.8 ± 1.0 days, <i>p</i> < 0.001). No significant difference was observed in the duration of vomiting (<i>p</i> = 0.061). <b>Conclusions:</b> Early initiation of macrolide antibiotics in children with <i>Campylobacter</i> enterocolitis significantly accelerated complete clinical resolution and shortened hospitalization, particularly by hastening the resolution of diarrhea, fever, and abdominal pain. These findings support the use of early macrolide therapy for pediatric <i>Campylobacter</i> enterocolitis.

AntibioticsVol. 15(2)
Catholic University of Korea (KR)
Good health and well-being
Openalex Percentile: Top 65%
Salmonella and Campylobacter epidemiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.